The safety risks of innovation: the FDA's Expedited Drug Development Pathway

JAMA. 2012 Sep 5;308(9):869-70. doi: 10.1001/jama.2012.9658.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anticoagulants / adverse effects
  • Anticoagulants / therapeutic use
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Benzimidazoles / adverse effects
  • Benzimidazoles / therapeutic use
  • Carcinoma, Neuroendocrine
  • Clinical Trials as Topic
  • Dabigatran
  • Drug Approval*
  • Efficiency, Organizational*
  • Fingolimod Hydrochloride
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use
  • Multiple Sclerosis / drug therapy
  • Patient Safety*
  • Piperidines / adverse effects
  • Piperidines / therapeutic use
  • Propylene Glycols / adverse effects
  • Propylene Glycols / therapeutic use
  • Quinazolines / adverse effects
  • Quinazolines / therapeutic use
  • Risk
  • Sphingosine / adverse effects
  • Sphingosine / analogs & derivatives
  • Sphingosine / therapeutic use
  • Stroke / prevention & control
  • Thyroid Neoplasms / drug therapy
  • Time Factors
  • United States
  • United States Food and Drug Administration*
  • beta-Alanine / adverse effects
  • beta-Alanine / analogs & derivatives
  • beta-Alanine / therapeutic use

Substances

  • Anticoagulants
  • Antineoplastic Agents
  • Benzimidazoles
  • Immunosuppressive Agents
  • Piperidines
  • Propylene Glycols
  • Quinazolines
  • beta-Alanine
  • Fingolimod Hydrochloride
  • Dabigatran
  • Sphingosine
  • vandetanib

Supplementary concepts

  • Thyroid cancer, medullary